Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on personalized cancer treatments, has announced a significant update to its Board of Directors. Jesper Høiland, a seasoned executive with over three decades of experience in the pharmaceutical industry, has been appointed to the board, effective immediately. This move comes as Joseph Vazzano prepares to step down on June 30, 2025, after two years of service.

Mr. Høiland's appointment is seen as a strategic addition to Allarity's leadership, given his extensive background in global pharmaceutical commercialization and executive roles. His tenure as President and EVP of Novo Nordisk's U.S. operations, along with leadership positions at Radius Health and Ascendis Pharma, underscores his capability to steer companies through critical phases of growth and development. Currently, he also holds board positions at SciBase Holding AB, ALK-Abello A/S, and Flen Health SA.

The transition occurs at a pivotal moment for Allarity, as the company advances its Phase 2 clinical trials for stenoparib, a novel dual PARP and WNT pathway inhibitor. Jerry McLaughlin, Chairman of the Board, expressed enthusiasm about Høiland's joining, highlighting the value of his experience during this period of clinical momentum. McLaughlin also extended gratitude to Vazzano for his contributions, particularly in strengthening the company's governance and operational focus.

Thomas Jensen, CEO of Allarity Therapeutics, remarked on the immediate impact Høiland has had since beginning his consultancy role in October 2024. Jensen emphasized Høiland's strategic advice and his deep understanding of the commercialization process for investigational drugs as key assets for Allarity's future. With Høiland's global network and leadership experience, Allarity is poised to navigate the challenges of bringing personalized cancer treatments to market.

TGS, the Oslo-based energy data provider, has been awarded a significant ocean bottom node (OBN) acquisition contract in the Gulf of Mexico, marking another strategic win in one of the company's core markets. The 4D monitor survey is scheduled to commence in the fourth quarter of 2025 and will span approximately four and a half months. This contract represents continued confidence in TGS's capabilities from the international oil company client, though the specific customer identity remains undisclosed.

The contract was notably absent from TGS's booked position disclosed in the company's second quarter 2025 presentation, indicating a recent acquisition for the seismic data specialist. The Gulf of Mexico remains a critical region for offshore energy production, and 4D seismic monitoring plays an essential role in optimizing reservoir management and production efficiency for major operators in the region.

Kristian Johansen, CEO of TGS, emphasized the significance of securing business from repeat customers, stating that the client values TGS's OBN technology and proven track record of project execution. "The client is confident we will deliver high-quality data and insights to optimize production from one of their highest producing facilities in the Gulf of Mexico," Johansen commented, highlighting the operational importance of the project for the customer's production optimization efforts.

TGS's expertise in OBN technology positions the company as a trusted partner for international oil companies seeking to maximize recovery from existing assets. The 4D seismic approach allows operators to monitor reservoir changes over time, providing critical data for production optimization decisions. This latest contract win reinforces TGS's strong position in the Gulf of Mexico market and demonstrates the ongoing demand for advanced seismic monitoring solutions in mature offshore basins.